KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 71 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $10,486,098 | +27.2% | 856,008 | 0.0% | 0.86% | -4.9% |
| Q3 2023 | $8,243,357 | +7.0% | 856,008 | 0.0% | 0.90% | +69.7% |
| Q2 2023 | $7,704,072 | +14.5% | 856,008 | 0.0% | 0.53% | +13.9% |
| Q1 2023 | $6,728,223 | +116164.4% | 856,008 | 0.0% | 0.47% | -29.9% |
| Q4 2022 | $5,787 | -100.0% | 856,008 | -44.2% | 0.67% | -72.9% |
| Q3 2022 | $22,252,000 | +47.5% | 1,533,559 | 0.0% | 2.46% | +62.2% |
| Q2 2022 | $15,090,000 | -33.2% | 1,533,559 | 0.0% | 1.52% | -2.7% |
| Q1 2022 | $22,605,000 | +11.4% | 1,533,559 | 0.0% | 1.56% | +27.3% |
| Q4 2021 | $20,289,000 | -29.2% | 1,533,559 | -6.6% | 1.22% | -4.9% |
| Q3 2021 | $28,651,000 | -35.8% | 1,641,913 | -11.9% | 1.29% | -33.5% |
| Q2 2021 | $44,645,000 | -6.7% | 1,863,296 | 0.0% | 1.93% | +14.9% |
| Q1 2021 | $47,868,000 | +55.8% | 1,863,296 | +15.1% | 1.68% | +22.7% |
| Q4 2020 | $30,731,000 | +65.3% | 1,618,296 | +9.6% | 1.37% | +27.7% |
| Q3 2020 | $18,593,000 | +4.1% | 1,476,796 | 0.0% | 1.07% | -16.2% |
| Q2 2020 | $17,869,000 | +58.2% | 1,476,796 | 0.0% | 1.28% | +25.2% |
| Q1 2020 | $11,297,000 | -62.5% | 1,476,796 | +8.7% | 1.02% | -63.7% |
| Q2 2019 | $30,105,000 | -22.6% | 1,359,149 | 0.0% | 2.82% | -27.3% |
| Q1 2019 | $38,899,000 | +44.9% | 1,359,149 | 0.0% | 3.88% | +13.2% |
| Q4 2018 | $26,843,000 | -10.7% | 1,359,149 | 0.0% | 3.43% | +13.2% |
| Q3 2018 | $30,051,000 | +1132.1% | 1,359,149 | +352.6% | 3.03% | +864.6% |
| Q2 2018 | $2,439,000 | -14.3% | 300,325 | 0.0% | 0.31% | -22.1% |
| Q1 2018 | $2,847,000 | -2.8% | 300,325 | 0.0% | 0.40% | -35.7% |
| Q4 2017 | $2,928,000 | +44.9% | 300,325 | 0.0% | 0.63% | +53.7% |
| Q3 2017 | $2,021,000 | -13.9% | 300,325 | 0.0% | 0.41% | -40.9% |
| Q1 2017 | $2,346,000 | +10.5% | 300,325 | 0.0% | 0.69% | -1.4% |
| Q4 2016 | $2,123,000 | – | 300,325 | – | 0.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,719,576 | $13,155,000 | 11.03% |
| INTERWEST VENTURE MANAGEMENT CO | 388,766 | $2,974,000 | 3.14% |
| Vivo Capital, LLC | 1,476,796 | $11,297,000 | 1.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 227,433 | $1,731,000 | 0.79% |
| DAFNA Capital Management LLC | 234,952 | $1,797,000 | 0.75% |
| Samsara BioCapital, LLC | 168,174 | $1,287,000 | 0.74% |
| Ghost Tree Capital, LLC | 350,000 | $2,678,000 | 0.71% |
| Ikarian Capital, LLC | 946,605 | $7,242,000 | 0.54% |
| Opaleye Management Inc. | 225,000 | $1,721,000 | 0.46% |
| Eventide Asset Management | 1,680,000 | $12,852,000 | 0.42% |